Genmab, AbbVie Face Setback as Epcoritamab Misses Survival Goal in Lymphoma Study
The drug is already approved in many countries for other lymphoma conditions and is marketed as Epkinly in the U.S. and Japan and as Tepkinly in the European Union.
Written By : sheeba farhat
Published On 2026-01-17 10:18 GMT | Update On 2026-01-17 10:18 GMT
Advertisement
Bengaluru: Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to improve the survival rate in patients in a late-stage study.
The study tested the drug, epcoritamab, in 483 patients with relapsed or refractory diffuse large B-cell lymphoma, who had already received at least one prior treatment and were not candidates for intensive chemotherapy followed by a stem cell transplant.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.